QUITO, Ecuador & AACHEN, Germany--(EON: Enhanced Online News)--The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, liquid pharmaceuticals. This GMP Certificate will be valid for another three years.
“We are very pleased that our colleagues at Grünenthal’s Tecnandina have again received this certification. It proves the sustainability and maturity of the quality system at our manufacturing site in Ecuador, which is permanently supported by Grünenthal’s global network. It is an important pillar in demonstrating our high quality capabilities in global contract manufacturing,” states Alberto Grua, Member of the Corporate Executive Board of Grünenthal.
Tecnandina S.A. belongs to the Grünenthal Group, an international, research-based, privately owned pharmaceutical company headquartered in Aachen, Germany. The Grünenthal Group offers contract manufacturing from its five production plants throughout Europe and Latin America. The site in Ecuador is Grünenthal’s central production facility and pharmaceutical development center in Latin America as well as Distribution Center for the Ecuadorian market.
More information: www.grunenthal-pro.com
About Tecnandina S.A., Ecuador
Tecnandina S.A. is the largest and most modern manufacturing plant for solid, semi-solid and liquid pharmaceuticals in Ecuador.
The organization is recognized as a preferred contract manufacturer throughout Latin America and logistics service provider in Ecuador. Various multinational corporations are customers of Tecnandina for many years. Tecnandina manufactures and exports to 17 countries in Central and South America as well as to Switzerland and offers integral solutions in manufacturing for third parties. The experts in Ecuador are able to manufacture a variety of formulations such as granules, coated tablets, capsules, liquids, semi-solids and packaging in various blister, sachet or bottle forms.
The plant of 50,000 m2 is certified by various Latin America authorities such as ANVISA (Brazil), INVIMA (Colombia) as well as by European authorities. More information: www.tecnandina.com and www.grunenthal-pro.com, respectively.
The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. We are an entrepreneurial specialist delivering true benefits to patients. By sustainably investing in research and development above the industrial average, we are committing to innovation in order to treat unmet medical needs and bring value-adding products to markets. Grünenthal is a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients.
Altogether, the Grünenthal Group is present in 32 countries with affiliates in Europe, Latin America and the US. Grünenthal products are sold in more than 155 countries and approx. 5,400 employees are working for the Grünenthal Group worldwide. In 2015, Grünenthal achieved revenues of € 1.2 bn. More information: www.grunenthal.com.